Matrix Asset Advisors, an asset management company, released its Q2 2026 investor letter. A copy of the letter can be downloaded here. The stock market rebounded strongly in the second quarter, with the S&P 500 gaining 15.2% in the quarter and 10.2% year-to-date. Investors overlooked inflation concerns exceeding 4% and geopolitical tensions, focusing instead on robust corporate earnings, AI-driven growth, easing energy prices, and a stable economy. In the second quarter, the Large Cap Value portfolio rose in the mid-teens, in line with the S&P 500 and slightly ahead of the Russell 1000 Value Index. Key contributors included Technology, Financials, and Industrials, while Consumer Staples and Healthcare lagged. The Dividend Income strategy posted high-single-digit gains, supported by the Financials, Technology, and Consumer Discretionary sectors. Fixed income delivered modestly positive returns in the second quarter. Matrix remains cautiously optimistic, expecting volatility but positioning portfolios for continued growth with attractive valuations and diversified exposure. In addition, please check the Fund’s top five holdings to know its best picks in 2026.
In its Q2 2026 investor letter, Matrix Asset Advisors highlighted Abbott Laboratories (NYSE:ABT). Abbott Laboratories (NYSE:ABT) is a global healthcare company that develops and manufactures medical devices, diagnostics, and nutritional products. On August 6, 2026, Abbott Laboratories (NYSE:ABT) closed at $107.96 per share, with a market capitalization of $186.81 billion. Abbott Laboratories (NYSE:ABT) posted a one-month return of 14.94%, while its shares lost 19.60% over the past 52 weeks.
Matrix Asset Advisors stated the following regarding Abbott Laboratories (NYSE:ABT) in its Q2 2026 investor letter:
“During the quarter, we started new partial positions in Abbott Laboratories (NYSE:ABT) and McDonald’s (MCD). ABT is a diversified global healthcare company that operates across four primary business segments: Medical Devices, Diagnostics, Nutrition, and Established Pharmaceuticals. We believe that the company is an attractive investment for the portfolio because of its recurring revenues, strong balance sheet, 54 years of dividend increases, and its price pullback from a 52-week high of $139 to its current price of under $90. At less than 16 times estimated 2026 earnings, the stock is trading at a 25% discount to the market and its own P/E multiple history. At our purchase price, the dividend yield was 2.8%.”
Abbott Laboratories (NYSE:ABT) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. As per our database, 73 hedge fund portfolios held Abbott Laboratories (NYSE:ABT) at the end of the fourth quarter, compared to 71 in the previous quarter. While we acknowledge the risk and potential of Abbott Laboratories (NYSE:ABT) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than Abbott Laboratories (NYSE:ABT) and that has 10,000% upside potential, check out our report about this cheapest AI stock.
In another article, we discussed Abbott Laboratories (NYSE:ABT) and shared a comparison between the company and Danaher Corporation regarding their earnings performance. In addition, please check out our hedge fund investor letters Q2 2026 page for more investor letters from hedge funds and other leading investors.
READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.
Disclosure: None. This article is originally published at Insider Monkey.
